Novartis: Phase 3 Trial Of Pluvicto Shows Positive Results In PSMA-positive MHSPC

Novartis (NVS) announced positive topline results from its Phase III PSMAddition trial of Pluvicto plus hormone therapy for metastatic hormone-sensitive prostate cancer (mHSPC), demonstrating a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) and a positive trend in overall survival compared to hormone therapy alone. The company plans to submit these results to the FDA in the second half of the year, potentially expanding Pluvicto's use to an earlier disease stage, as it is already approved for metastatic castration-resistant prostate cancer (mCRPC). This marks the third successful Phase III trial for Pluvicto, reinforcing Novartis's position in radioligand therapy for advanced prostate cancer.

Analysis

Novartis AG (NVS) announced positive topline results from its Phase III PSMAddition trial, where Pluvicto combined with hormone therapy demonstrated a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) for patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared to hormone therapy alone; a positive trend in overall survival was also observed. This outcome is critical as Pluvicto, an intravenous radioligand therapy (RLT), is currently approved for metastatic castration-resistant prostate cancer (mCRPC), and these new data support its potential use in an earlier stage of prostate cancer, addressing the progression from mHSPC to mCRPC, a significant unmet need. Novartis intends to submit these findings to the U.S. Food and Drug Administration for regulatory review in the second half of the year. This marks the third successful Phase III trial for Pluvicto, following the VISION and PSMAfore studies, reinforcing its efficacy and Novartis's position as a leader in PSMA-targeted RLTs. The company is also exploring Pluvicto in earlier prostate cancer stages and developing a broader portfolio of RLTs for other advanced cancers, supported by investments in manufacturing. The reported strongly positive sentiment (0.85 for NVS) and high market impact score (0.75) underscore the perceived clinical and commercial significance of this development.

Key Decisions for Investors

• Investors should view these positive Phase III results as a potential driver for Pluvicto's market expansion and increased revenue contribution for Novartis, contingent on regulatory approval for the mHSPC indication.
• Closely monitor the planned FDA submission in the second half of the year and the subsequent regulatory outcome, as approval would significantly broaden Pluvicto's addressable patient population in an earlier treatment setting.
• Consider Novartis's ongoing commitment and progress in its broader radioligand therapy pipeline, including manufacturing investments, as a key component of its long-term oncology growth strategy and a potential source of further value creation.